MTOR and cancer: Morevoer, we demonstrate that cancer-associated MTOR mutations in the FAT domain confer a proliferative advantage over wild type MTOR. Finally, our data demonstrate that these mutations can promote persistent mTOR activity despite rapalog therapy.